Pharmaceuticals News and Research

RSS

The world generic drug market is expected to grow 10-15% annually

Currently, the world generic drug market is approaching $40 billion. Over the next five years, the market is expected to grow 10-15% annually.

6 May 2004

Vitrase has been approved for use as an adjunct to rehydrating agents

The Food and Drug Administration approved Vitrase (hyaluronidase for injection). Vitrase is an injectable drug approved as an adjunct to (in combination with) other injected drugs to increase their absorption and dispersion. Hyaluronidase has been used most commonly in combination with local anesthetics in the setting of ophthalmic (eye) surgery.

6 May 2004

Experimental sleep drug eszopiclone helps elderly to sleep better

Older people with insomnia slept better and longer after taking an experimental sleep medication, according to research at Wake Forest University Baptist Medical Center.

6 May 2004

A second-generation targetted antibody for potential cancer therapy

The overproduction, or 'overexpression', of the epidermal growth factor receptor (EGFR) is one of the most common aberrations in cancer, and subsequently agents that inhibit EGFR are among the most hotly-pursued potential products in the pharmaceutical industry.

6 May 2004

New guidelines for using new antiepileptic drugs to treat epilepsy

The number of drugs available to treat epilepsy have more than doubled in the last decade. The American Academy of Neurology and the American Epilepsy Society have assembled the top experts in the field to evaluate the available data of 1,462 research articles in order to create a guideline for the treatment of epilepsy with the new antiepileptic drugs (AEDs).

6 May 2004

Ritalin drug used to treat hyperactive children boosts the potency of Parkinson's drug levodopa

A well-known drug used to treat hyperactive children boosts the potency of another drug that reduces Parkinson's disease symptoms, an Oregon Health & Science University study has found.

6 May 2004

World's first gene therapy trial aimed at preventing cancer

The concept seems straightforward. If, at its heart, cancer is a disease of genes, then giving patients new genes should disarm cancer. Such treatment would replace missing or faulty genes that keep cell growth in check, or would flush the body with "super genes" that could attack and destroy cancer.

5 May 2004

Immtech signs agreement with CombinatoRx to test Immtech compounds as potential cancer treatment

Immtech International, Inc. announced today that it signed an agreement with CombinatoRx of Boston, Massachusetts to screen its lead aromatic cationic compounds, DB289 and DB75, for activity against various cancers.

5 May 2004

Agreement expands Quintiles capabilities to support drug approvals in Japan

Quintiles Transnational Corp. today announced an agreement to conduct clinical trials in Peru involving ethnic Japanese, further expanding the company's ability to support new drug applications in Japan.

5 May 2004

IT has the power to transform the pharmaceutical industry

Information technology has the power to transform the pharmaceutical industry, if businesses apply it correctly. That’s the conclusion of Pharma 2010: Silicon Reality, a report from IBM Business Consulting Services (BCS).

5 May 2004

Mylan announces FDA approval of Parkinson’s disease drug

The FDA approval clears the way for Bertek to market APOKYN and provides a new therapy for “off” episodes, one of the most debilitating aspects suffered by patients with Parkinson’s disease.

5 May 2004

$FDA approves INFUSE® bone graft which improves fracture healing$

FDA approves INFUSE® bone graft which improves fracture healing

Medtronic, Inc. has announced that the U.S. Food and Drug Administration (FDA) approved the use of INFUSE® Bone Graft in the treatment of acute, open fractures of the tibial shaft, a long bone in the lower leg. The approval broadens the indications for INFUSE Bone Graft, a product that has been used since 2002 in spinal surgery with metallic cages to treat tens of thousands of patients.

4 May 2004

New hope for advances in treatment methods for AIDS, Alzheimer's and age-related blindness

Pharmaceutical science leaders from the FDA, research institutions and top pharmaceutical companies will gather at the 2004 AAPS National Biotechnology Conference, AAPS' spring annual meeting.

4 May 2004

Pfizer targets five internet sites for selling an unapproved copy of Pfizer's top selling cholesterol medicine, Lipitor

Pfizer has filed lawsuits against the operators of five internet sites for selling an unapproved copy of Pfizer's top selling cholesterol medicine, Lipitor, the company said today.

4 May 2004

FDA to create database to help identify counterfeit pharmaceutical brands

The US Food and Drug Administration (FDA) is planning to create a database of the major pharmaceutical brands on the US market, to make it easier to establish the authenticity of suspect products and identify counterfeit versions that enter the supply chain.

3 May 2004

Schering-Plough Corporation settles with $27 million to the State of Texas

Schering-Plough Corporation has announced that it has reached an agreement with the Attorney General's Office of the State of Texas to settle issues related to reimbursement by Texas' Medicaid program of albuterol sulfate solution and inhaler products.

3 May 2004

Minimal information available on the likelihood of side effects from prostate cancer treatment

When a man is diagnosed with early-stage prostate cancer, he must decide among four different treatment methods, each of which carries its own set of benefits and risks.

3 May 2004

Wyeth gets FDA approval for a novel protein device that enhances bone healing

Wyeth have announced that the FDA has approved rhBMP-2/ACS (recombinant human Bone Morphogenetic Protein-2/Absorbable Collagen Sponge), a novel protein device that enhances bone healing, for use in the treatment of acute, open tibia shaft fractures in adults.

3 May 2004

Conference to discuss the ethical, social and legal aspects of human genetic testing

On 6 and 7 May 2004, the European Commission is inviting all interested parties to attend a European citizens’ and stakeholders’ conference to discuss the ethical, social and legal aspects of human genetic testing in research and healthcare applications.

3 May 2004

Bush on healthcare

The way I like to kind of try to describe health care is, on the research side, we're the best. We're coming up with more innovative ways to save lives and to treat patients.

1 May 2004